Hui Fang Liu
Corporate Officer/Principal at Beijing Mabworks Biotech Co., Ltd.
Profile
Hui Fang Liu is currently the Vice President & Deputy General Manager at Beijing Mabworks Biotech Co., Ltd.
Prior to this, she worked as a Manager at Genentech, Inc. from 2007 to 2011 and as a Manager-Process Research & Development at Tanox, Inc. from 2001 to 2007.
Dr. Liu holds a doctorate degree from Nancy-Université, which she obtained in 1993, and an undergraduate degree from Beijing Medical University, which she obtained in 1982.
Hui Fang Liu active positions
Companies | Position | Start |
---|---|---|
Beijing Mabworks Biotech Co., Ltd.
Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Corporate Officer/Principal | 2016-11-30 |
Former positions of Hui Fang Liu
Companies | Position | End |
---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2010-12-31 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Corporate Officer/Principal | 2006-12-31 |
Training of Hui Fang Liu
Nancy-Université | Doctorate Degree |
Beijing Medical University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Beijing Mabworks Biotech Co., Ltd.
Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
- Stock Market
- Insiders
- Hui Fang Liu